← Insider buys
KALV

KalVista Pharmaceuticals, Inc. · Healthcare

Chief Development Officer Christopher Yea sold $90K of KalVista Pharmaceuticals, Inc.

Sold$90,328
$18.07Price
5,000Shares
−13%Stake

What KALV did after the filing

Prices for KALV after this filing aren't in yet.

Traded Mon, Nov 1. Filed Wed, Nov 3, 12:56 PM ET, during the session. Not investment advice.